Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Hyperlipidemia Market Valuation Change Between Now And 2029?

In the past years, the hyperlipidemia market has consistently expanded. From $20.24 billion in 2024, it is predicted to increase to $20.92 billion in 2025, with a compound annual growth rate (CAGR) of 3.4%. The rise in the historical phase can be credited to the escalating need for effective treatments, geographical expansion, heightened public consciousness of hyperlipidemia, and tobacco utilization.

In the coming years, the hyperlipidemia market is projected to experience consistent growth, reaching a value of $24.24 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 3.8%. This growth within the forecast period is linked to an increased need for hyperlipidemia medications, worldwide health initiatives, an aging demographic, proactive prevention and early intervention measures. Key trends during this period involve innovative therapies, the implementation of digital health technologies for managing hyperlipidemia, the use of biomarkers for diagnosing and treating the condition, and the ongoing research and development efforts in the pharmaceutical sector for treatments.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

What Underlying Factors Are Supporting The Hyperlipidemia Market Growth?

The hyperlipidemia market is expected to grow due to the increasing occurrence of chronic diseases like heart disease. Heart disease, which affects the heart and its functioning, is effectively managed by hyperlipidemia treatment. This treatment not only reduces the risk of heart attacks in individuals with heart disease, but also prevents strokes, enhances endothelial function, and decreases the need for invasive interventions. For example, data from the British Heart Foundation, a cardiovascular research charity based in the UK, revealed that in September 2024, about 7.6 million individuals in the UK were living with heart and circulatory diseases. This included around 4 million males and 3.6 million females. These diseases accounted for nearly 27% of all UK deaths, resulting in over 170,000 deaths per year, or about 480 deaths daily, which is equivalent to one death every three minutes. Hence, the rising occurrence of chronic heart disease is propelling the expansion of the hyperlipidemia market.

Which Sub-Segments Are Driving Growth Within The Hyperlipidemia Market?

The hyperlipidemiamarket covered in this report is segmented –

1) By Type: Familial; Acquired

2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment

3) By Route of Administration: Oral; Parenteral

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Subsegments:

1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH); Familial Combined Hyperlipidemia; Familial Dysbetalipoproteinemia

2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia; Secondary Hyperlipidemia; Drug-Induced Hyperlipidemia

What Future-Focused Trends Are Anticipated In The Hyperlipidemia Market?

In the hyperlipidemia market, dominant corporations are honing their focus on the creation of novel and advanced products, such as innovative therapies aimed at the reduction of low-density lipoprotein cholesterol. To secure their market standing, they invest in development and innovation, as demonstrated by Regeneron Pharmaceuticals, Inc., a biotech firm based in the US. They garnered the approval of the U.S. Food & Drug Administration (FDA) for their Praluent (alirocumab) Injection in March 2024. This development significantly enhances the treatment approach for heterozygous familial hypercholesterolemia (HeFH) in pediatric patients who are 8 years old and above, providing a specialized method to control perilously elevated low-density lipoprotein cholesterol (LDL-C) levels. This FDA approval was backed by the encouraging results of a Phase 3 trial, which reported a 31% decline in LDL-C levels with consistent doses. The safety profile of Praluent, which aligns with adult applications, provides confidence for families and medical practitioners. Furthermore, Praluent’s status as the pioneering therapy that targets the genetically-confirmed PCSK9 protein represents a significant stride in addressing heart disease. These combined elements secure Praluent’s position as a key resource in the management of high cholesterol in kids diagnosed with HeFH.

Which Companies Hold A Competitive Edge In The 631 Market?

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Which Region Dominates The Hyperlipidemia Market Today?

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12873&type=smp

Browse Through More Reports Similar to the Global Hyperlipidemia Market 2025, By The Business Research Company

Fatty Acids Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fatty-acids-global-market-report

Fats And Oils Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fats-and-oils-global-market-report

Body Fat Reduction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model